| Literature DB >> 26685026 |
Christina Howitt1, Ian R Hambleton1, Angela M C Rose1, Anselm Hennis2, T Alafia Samuels3, Kenneth S George4, Nigel Unwin5.
Abstract
OBJECTIVE: To describe the distribution of diabetes, hypertension and related behavioural and biological risk factors in adults in Barbados by gender, education and occupation.Entities:
Keywords: EPIDEMIOLOGY
Mesh:
Year: 2015 PMID: 26685026 PMCID: PMC4691788 DOI: 10.1136/bmjopen-2015-008869
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Definition of diabetes, hypertension and associated risk factors
| Risk factor | Definition |
|---|---|
| Diabetes | Self-reported doctor-diagnosed diabetes or fasting blood glucose ≥7 mmol/L |
| Hypertension | Self-reported current use of antihypertensive medication, or a systolic blood pressure ≥140 mm Hg, or a diastolic blood pressure ≥90 mm Hg |
| Current tobacco use | Self-reported use of any tobacco products, including cigarettes, cigars or pipes |
| Heavy episodic alcohol consumption | Self-reported consumption of at least 4 (for females) or 5 (for males) standard alcoholic drinks in a single drinking occasion at least once in the past 30 days |
| Inadequate fruit and vegetable intake | Self-reported intake of less than 5 servings of fruit and/or vegetables per day |
| Physical inactivity | Self-reported activity of less than 150 min of moderate intensity per week, assessed by the Recent Physical Activity Questionnaire |
| Obesity | Body mass index of 30 kg/m2 or more |
| Hypercholesterolaemia | Total cholesterol of 5 mmol/L or more |
Figure 1Survey recruitment.
Selected sociodemographic characteristics of the survey sample, by sex and collectively*
| Women | Men | Overall | ||||
|---|---|---|---|---|---|---|
| n | Per cent | n | Per cent | n | Per cent | |
| Age (years) | ||||||
| 25–44 | 292 | 39.4 | 158 | 36.2 | 450 | 38.2 |
| 45–64 | 310 | 41.4 | 206 | 44.0 | 516 | 42.4 |
| 65 and older | 162 | 19.2 | 106 | 19.8 | 268 | 19.4 |
| Level of education | ||||||
| Less than secondary school | 150 | 18.1 | 82 | 14.0 | 232 | 16.6 |
| Secondary school completed | 296 | 40.9 | 211 | 47.3 | 507 | 43.3 |
| Technical, trade or teacher education | 123 | 16.1 | 80 | 16.7 | 203 | 16.3 |
| University education | 195 | 24.9 | 97 | 22.0 | 292 | 23.8 |
| Occupational category | ||||||
| Routine/manual | 123 | 15.1 | 185 | 39.1 | 308 | 24.1 |
| Intermediate | 256 | 33.7 | 93 | 17.6 | 349 | 27.6 |
| Professional | 144 | 18.2 | 78 | 19.2 | 222 | 18.6 |
| Not in employment, not retired† | 152 | 21.5 | 49 | 10.3 | 201 | 17.3 |
| Occupation code unavailable‡ | 89 | 11.5 | 65 | 14.0 | 154 | 12.4 |
| Total | 764 | 100 | 470 | 100 | 1234 | 100 |
*Percentages are weighted to compensate for unequal probabilities of selection (selecting one individual from household) and for non-response.
†Includes people on maternity or sick leave (n=6); people looking for work (n=85); home duties (n=74); students (n=8); incapacitated people (n=28).
‡Includes people who reported occupation, but that occupation was not listed in Barbados Standard Occupational Classification (BARSOC) coding, as well as retired people who did not report main lifetime occupation.
Sex-specific and overall prevalence of diabetes, hypertension and associated risk factors in the adult Barbadian population, with age-adjusted prevalence ratios (PRs) for men versus women
| Women | Men | Overall | |
|---|---|---|---|
| Current tobacco use | |||
| Prevalence (%) (95% CI) | 3.7 (2.3 to 6.1) | 15.5 (11.9 to 20.0) | 9.2 (7.2 to 11.7) |
| PR (95% CI) | 1.00* | 4.08 (2.48 to 6.69) | – |
| Heavy episodic alcohol consumption | |||
| Prevalence (%) (95% CI) | 5.4 (3.2 to 8.8) | 25.4 (21.0 to 30.3) | 14.5 (12.0 to 17.4) |
| PR (95% CI) | 1.00* | 4.55 (2.70 to 7.58) | – |
| Inadequate fruit and vegetable intake | |||
| Prevalence (%) (95% CI) | 88.5 (85.1 to 91.2) | 91.8 (87.0 to 95.0) | 90.0 (87.0 to 92.4) |
| PR (95% CI) | 1.00* | 1.39 (0.87 to 2.23) | – |
| Physical inactivity | |||
| Prevalence (%) (95% CI) | 67.2 (63.1 to 71.1) | 30.0 (24.6 to 36.1) | 49.9 (46.1 to 53.7) |
| PR (95% CI) | 1.00* | 0.47 (0.39 to 0.57) | – |
| Obesity | |||
| Prevalence (%) (95% CI) | 43.4 (39.5 to 47.3) | 23.4 (18.9 to 28.5) | 33.8 (30.7 to 37.1) |
| PR (95% CI) | 1.00* | 0.53 (0.42 to 0.67) | – |
| Hypercholesterolaemia | |||
| Prevalence (%) (95% CI) | 22.9 (19.1 to 27.1) | 19.3 (15.1 to 24.2) | 21.2 (18.4 to 24.2) |
| PR (95% CI) | 1.00* | 0.84 (0.62 to 1.13) | – |
| Hypertension | |||
| Prevalence (%) (95% CI) | 44.0 (38.8 to 49.2) | 36.9 (30.9 to 43.3) | 40.7 (36.5 to 44.9) |
| PR (95% CI) | 1.00* | 0.89 (0.79 to 1.02) | – |
| Diabetes | |||
| Prevalence (%) (95% CI) | 21.0 (18.2 to 24.2) | 15.9 (12.0 to 20.8) | 18.7 (16.2 to 21.4) |
| PR (95% CI) | 1.00* | 0.83 (0.65 to 1.05) | – |
*Denotes the reference group for the PR.
Prevalence and adjusted prevalence ratios (PRs) of diabetes, hypertension and associated risk factors by age group in the adult Barbadian population
| Age group | |||
|---|---|---|---|
| 25–44 years | 45–64 years | 65+years | |
| Women | |||
| Prevalence (%) (95% CI) | 4.3 (1.9 to 9.3) | 2.7 (1.4 to 5.4) | 4.4 (1.8 to 10.4) |
| PR (95% CI) | 1.00* | 0.64 (0.22 to 1.84) | 1.02 (0.3 to 3.46) |
| Men | |||
| Prevalence (%) (95% CI) | 20.8 (14.4 to 29.2) | 13.4 (9.2 to 19.1) | 5.3 (2.4 to 11.5) |
| PR (95% CI) | 1.00* | 0.64 (0.40 to 1.04) | 0.26 (0.1 to 0.62) |
| Total | |||
| Prevalence (%) (95% CI) | 12.2 (8.8 to 16.7) | 7.8 (5.6 to 10.8) | 4.7 (2.6 to 8.6) |
| PR (95% CI) | 1.00* | 0.64 (0.42 to 0.98) | 0.42 (0.23 to 0.77) |
| Women | |||
| Prevalence (%) (95% CI) | 8.5 (4.4 to 15.9) | 3.4 (2.1 to 5.5) | 2.2 (0.7 to 7) |
| PR (95% CI) | 1.00* | 0.40 (0.19 to 0.85) | 0.26 (0.07 to 0.96) |
| Men | |||
| Prevalence (%) (95% CI) | 33.2 (24.6 to 43.0) | 23.4 (17.5 to 30.5) | 8.6 (4.4 to 16) |
| PR (95% CI) | 1.00* | 0.70 (0.47 to 1.07) | 0.26 (0.12 to 0.54) |
| Total | |||
| Prevalence (%) (95% CI) | 20.0 (15.1 to 26.0) | 12.9 (10 to 16.5) | 4.8 (2.8 to 8.1) |
| PR (95% CI) | 1.00* | 0.65 (0.45 to 0.94) | 0.26 (0.15 to 0.47) |
| Women | |||
| Prevalence (%) (95% CI) | 90.2 (85.6 to 93.5) | 88.8 (83.8 to 92.4) | 83.9 (75 to 90.1) |
| PR (95% CI) | 1.00* | 0.87 (0.5 to 1.5) | 0.61 (0.34 to 1.08) |
| Men | |||
| Prevalence (%) (95% CI) | 91.6 (84.5 to 95.6) | 92.5 (86.9 to 95.8) | 91.0 (80.2 to 96.2) |
| PR (95% CI) | 1.00* | 1.12 (0.66 to 1.88) | 0.94 (0.32 to 2.78) |
| Total | |||
| Prevalence (%) (95% CI) | 90.9 (86.4 to 94) | 90.5 (87.4 to 92.9) | 86.8 (80 to 91.5) |
| PR (95% CI) | 1.00* | 0.96 (0.66 to 1.41) | 0.70 (0.4 to 1.23) |
| Women | |||
| Prevalence (%) (95% CI) | 63.6 (56.5 to 70.19) | 62.6 (55.19 to 69.4) | 83.0 (76.02 to 88.24) |
| PR (95% CI) | 1.00* | 0.98 (0.84 to 1.16) | 1.31 (1.15 to 1.5) |
| Men | |||
| Prevalence (%) (95% CI) | 17.5 (10.09 to 28.59) | 35.4 (26.63 to 45.24) | 53.7 (40.33 to 66.47) |
| PR (95% CI) | 1.00* | 2.00 (1.07 to 3.72) | 3.09 (1.72 to 5.53) |
| Total | |||
| Prevalence (%) (95% CI) | 41.5 (35.94 to 47.25) | 49.6 (42.79 to 56.48) | 71.1 (63.3 to 77.77) |
| PR (95% CI) | 1.00* | 1.11 (0.95 to 1.3) | 1.47 (1.26 to 1.72) |
| Women | |||
| Prevalence (%) (95% CI) | 45.9 (38.8 to 53.3) | 42.7 (37 to 48.7) | 39.1 (30.6 to 48.2) |
| PR (95% CI) | 1.00* | 0.93 (0.74 to 1.17) | 0.85 (0.65 to 1.12) |
| Men | |||
| Prevalence (%) (95% CI) | 24.1 (16.5 to 33.9) | 25.7 (19.1 to 33.6) | 15.5 (8.8 to 26) |
| PR (95% CI) | 1.00* | 1.06 (0.65 to 1.74) | 0.64 (0.35 to 1.2) |
| Total | |||
| Prevalence (%) (95% CI) | 35.0 (28.9 to 41.5) | 34.6 (29.6 to 40) | 29.4 (23.7 to 35.8) |
| PR (95% CI) | 1.00* | 0.97 (0.76 to 1.22) | 0.80 (0.62 to 1.04) |
| Women | |||
| Prevalence (%) (95% CI) | 15.5 (10.9 to 21.6) | 27.3 (22.3 to 33.0) | 31.1 (23.2 to 40.3) |
| PR (95% CI) | 1.00* | 1.76 (1.23 to 2.53) | 2.01 (1.29 to 3.11) |
| Men | |||
| Prevalence (%) (95% CI) | 17.5 (10.9 to 27) | 22.2 (15.3 to 31.3) | 17.2 (10.0 to 28.0) |
| PR (95% CI) | 1.00* | 1.27 (0.44 to 0.69) | 0.98 (0.96 to 0.48) |
| Total | |||
| Prevalence (%) (95% CI) | 16.5 (12.7 to 21.2) | 24.9 (20.7 to 29.6) | 25.2 (19.9 to 31.5) |
| PR (95% CI) | 1.00* | 1.52 (1.12 to 2.06) | 1.53 (1.08 to 2.17) |
| Women | |||
| Prevalence (%) (95% CI) | 16.2 (11.2 to 22.7) | 56.5 (49.3 to 63.5) | 80.9 (73.0 to 86.9) |
| PR (95% CI) | 1.00* | 3.50 (2.51 to 4.87) | 5.01 (3.48 to 7.22) |
| Men | |||
| Prevalence (%) (95% CI) | 14.1 (8.8 to 21.9) | 48.9 (40.2 to 57.6) | 74.3 (63.8 to 82.6) |
| PR (95% CI) | 1.00* | 3.47 (2.16 to 5.56) | 5.27 (3.26 to 8.52) |
| Total | |||
| Prevalence (%) (95% CI) | 15.2 (11.3 to 20.0) | 52.9 (47.4 to 58.3) | 78.2 (71.8 to 83.5) |
| PR (95% CI) | 1.00* | 3.49 (2.66 to 4.58) | 5.10 (3.85 to 6.76) |
| Women | |||
| Prevalence (%) (95% CI) | 6.6 (3.7 to 11.3) | 23.0 (18.1 to 28.8) | 48.0 (37.6 to 58.7) |
| PR (95% CI) | 1.00* | 3.51 (1.82 to 6.8) | 7.32 (3.87 to 13.87) |
| Men | |||
| Prevalence (%) (95% CI) | 1.5 (0.4 to 4.6) | 21.2 (14.5 to 30.0) | 42.4 (32.1 to 53.3) |
| PR (95% CI) | 1.00* | 14.60 (4.53 to 47.02) | 29.11 (8.55 to 99.14) |
| Total | |||
| Prevalence (%) (95% CI) | 4.2 (2.5 to 6.9) | 22.2 (17.7 to 27.3) | 45.7 (38.2 to 53.4) |
| PR (95% CI) | 1.00* | 5.31 (2.90 to 9.70) | 10.82 (6.23 to 19.00) |
*Denotes the reference group for the PR.
Prevalence and age-adjusted prevalence ratios (PRs) of diabetes, hypertension and associated risk factors by education level in the adult Barbadian population
| Level 1: Less than secondary school | Level 2: Secondary school completed | Level 3: Technical, trade or teacher education | Level 4: University | |
|---|---|---|---|---|
| Women | ||||
| Prevalence (%) (95% CI) | 4.4 (2.1 to 8.7) | 4.1 (1.9 to 8.5) | 3.1 (1.2 to 7.7) | 3.2 (0.8 to 11.4) |
| PR (95% CI) | 1.00* | 0.91 (0.29 to 2.91) | 0.65 (0.19 to 2.19) | 0.66 (0.21 to 2.02) |
| Men | ||||
| Prevalence (%) (95% CI) | 19.8 (11.1 to 32.9) | 18.4 (13 to 25.3) | 16.4 (8.4 to 29.5) | 5.7 (2.3 to 13.7) |
| PR (95% CI) | 1.00* | 0.55 (0.3 to 1.02) | 0.49 (0.22 to 1.08) | 0.18 (0.05 to 0.58) |
| Total | ||||
| Prevalence (%) (95% CI) | 10.4 (6.9 to 15.2) | 11.3 (8.2 to 15.3) | 9.8 (5.3 to 17.6) | 4.2 (1.7 to 10.1) |
| PR (95% CI) | 1.00* | 0.60 (0.35 to 1.03) | 0.52 (0.24 to 1.1) | 0.25 (0.09 to 0.69) |
| Women | ||||
| Prevalence (%) (95% CI) | 3.3 (1.1 to 9.8) | 7.1 (3.2 to 14.9) | 2.9 (1.2 to 7.2) | 5.8 (3.0 to 10.9) |
| PR (95% CI) | 1.00* | 1.32 (0.39 to 4.43) | 0.51 (0.1 to 2.55) | 0.85 (0.25 to 2.89) |
| Men | ||||
| Prevalence (%) (95% CI) | 18.2 (11.1 to 28.4) | 30.7 (23.7 to 38.6) | 28.4 (15.8 to 45.6) | 15.2 (8.3 to 26.4) |
| PR (95% CI) | 1.00* | 1.15 (0.61 to 2.17) | 1.07 (0.49 to 2.33) | 0.59 (0.26 to 1.31) |
| Total | ||||
| Prevalence (%) (95 % CI) | 9.0 (6.0 to 13.3) | 18.8 (14.2 to 24.7) | 15.5 (8.6 to 26.5) | 9.7 (6.2 to 14.9) |
| PR (95% CI) | 1.00* | 1.17 (0.65 to 2.12) | 0.99 (0.5 to 1.97) | 0.66 (0.36 to 1.2) |
| Women | ||||
| Prevalence (%) (95% CI) | 92.9 (84.7 to 96.8) | 92.9 (89.4 to 95.3) | 83.3 (69.8 to 91.5) | 81.9 (75.4 to 86.9) |
| PR (95% CI) | 1.00* | 0.73 (0.29 to 1.81) | 0.33 (0.13 to 0.82) | 0.24 (0.1 to 0.61) |
| Men | ||||
| Prevalence (%) (95% CI) | 87.0 (71.8 to 94.6) | 96.1 (91.6 to 98.2) | 85.1 (70.2 to 93.3) | 90.9 (76.4 to 96.8) |
| PR (95% CI) | 1.00* | 3.52 (1.05 to 11.83) | 0.93 (0.32 to 2.69) | 1.48 (0.37 to 5.9) |
| Total | ||||
| Prevalence (%) (95% CI) | 90.7 (83.6 to 94.9) | 94.5 (91.8 to 96.4) | 84.2 (73.6 to 91.1) | 85.6 (79.2 to 90.3) |
| PR (95% CI) | 1.00* | 1.35 (0.61 to 2.96) | 0.48 (0.22 to 1.04) | 0.50 (0.24 to 1.07) |
| Women | ||||
| Prevalence (%) (95% CI) | 83.2 (74.1 to 89.5) | 65.9 (59.3 to 71.9) | 68.0 (57.2 to 77.2) | 57.1 (49.1 to 64.7) |
| PR (95% CI) | 1.00* | 0.86 (0.74 to 1.01) | 0.84 (0.72 to 0.99) | 0.75 (0.61 to 0.91) |
| Men | ||||
| Prevalence (%) (95% CI) | 43.9 (30.8 to 57.8) | 30.6 (23.6 to 38.6) | 21.5 (10.6 to 38.6) | 27.9 (18.9 to 39.1) |
| PR (95% CI) | 1.00* | 1.02 (0.69 to 1.51) | 0.77 (0.38 to 1.57) | 0.89 (0.58 to 1.35) |
| Total | ||||
| Prevalence (%) (95% CI) | 68.0 (58.4 to 76.3) | 48.1 (43 to 53.3) | 44.5 (34.1 to 55.5) | 44.9 (39.2 to 50.8) |
| PR (95% CI) | 1.00* | 0.90 (0.79 to 1.03) | 0.83 (0.7 to 0.99) | 0.80 (0.68 to 0.95) |
| Women | ||||
| Prevalence (%) (95% CI) | 34.7 (28.3 to 41.6) | 49.8 (43.2 to 56.5) | 40.7 (29.8 to 52.6) | 41.0 (32.3 to 50.2) |
| PR (95% CI) | 1.00* | 1.41 (1.08 to 1.84) | 1.14 (0.8 to 1.62) | 1.12 (0.78 to 1.61) |
| Men | ||||
| Prevalence (%) (95% CI) | 19.2 (10.3 to 33) | 26.6 (19.7 to 34.9) | 22.2 (12.7 to 36.1) | 19.6 (12.6 to 29.4) |
| PR (95% CI) | 1.00* | 1.21 (0.6 to 2.45) | 1.01 (0.48 to 2.13) | 0.87 (0.41 to 1.85) |
| Total | ||||
| Prevalence (%) (95% CI) | 28.6 (23.1 to 34.8) | 37.8 (32.4 to 43.6) | 31.2 (23.8 to 39.8) | 31.7 (25.7 to 38.5) |
| PR (95% CI) | 1.00* | 1.34 (1.02 to 1.76) | 1.11 (0.81 to 1.52) | 1.05 (0.78 to 1.43) |
| Women | ||||
| Prevalence (%) (95% CI) | 34.1 (25.1 to 44.4) | 23.9 (17.7 to 31.4) | 19.4 (11.5 to 30.7) | 16.1 (11.7 to 21.8) |
| PR (95% CI) | 1.00* | 0.81 (0.53 to 1.23) | 0.69 (0.38 to 1.25) | 0.62 (0.4 to 0.96) |
| Men | ||||
| Prevalence (%) (95% CI) | 13.13 (6.4 to 25) | 21.39 (14.7 to 30.1) | 20.63 (11.7 to 33.7) | 17.46 (10.6 to 27.4) |
| PR (95% CI) | 1.00* | 1.69 (0.77 to 3.69) | 1.66 (0.64 to 4.3) | 1.34 (0.52 to 3.48) |
| Total | ||||
| Prevalence (%) (95% CI) | 25.54 (18.4 to 34.3) | 22.66 (18.4 to 27.6) | 19.98 (13.3 to 28.8) | 16.68 (12.5 to 21.9) |
| PR (95% CI) | 1.00* | 0.99 (0.66 to 1.48) | 0.90 (0.54 to 1.52) | 0.75 (0.47 to 1.22) |
| Women | ||||
| Prevalence (%) (95% CI) | 67.6 (57.9 to 75.9) | 44.9 (36.5 to 53.6) | 41.2 (31.2 to 52) | 28.1 (21.3 to 35.9) |
| PR (95% CI) | 1.00* | 1.07 (0.9 to 1.26) | 1.00 (0.84 to 1.18) | 0.92 (0.66 to 1.27) |
| Men | ||||
| Prevalence (%) (95% CI) | 65.9 (52.4 to 77.3) | 32.9 (25.3 to 41.5) | 23.8 (15.3 to 35.1) | 40.3 (27.6 to 54.5) |
| PR (95% CI) | 1.00* | 0.85 (0.66 to 1.08) | 0.65 (0.41 to 1.02) | 0.89 (0.66 to 1.2) |
| Total | ||||
| Prevalence (%) (95% CI) | 66.9 (58.5 to 74.4) | 38.8 (33.1 to 44.8) | 32.4 (25.0 to 40.9) | 33.2 (26.5 to 40.6) |
| PR (95% CI) | 1.00* | 0.99 (0.85 to 1.16) | 0.88 (0.73 to 1.06) | 0.94 (0.76 to 1.16) |
| Women | ||||
| Prevalence (%) (95% CI) | 43.0 (34.9 to 51.6) | 18.0 (13.2 to 24.0) | 20.3 (13.2 to 30.0) | 10.8 (6.7 to 17.0) |
| PR (95% CI) | 1.00* | 0.74 (0.5 to 1.1) | 0.76 (0.52 to 1.12) | 0.58 (0.36 to 0.95) |
| Men | ||||
| Prevalence (%) (95% CI) | 25.0 (16.8 to 35.3) | 15.0 (9.9 to 22.1) | 13.0 (6.5 to 24.4) | 14.8 (8.5 to 24.6) |
| PR (95% CI) | 1.00* | 1.34 (0.82 to 2.17) | 1.23 (0.70 to 2.17) | 1.29 (0.69 to 2.40) |
| Total | ||||
| Prevalence (%) (95% CI) | 35.9 (29.2 to 43.1) | 16.5 (13.3 to 20.4) | 16.7 (10.8 to 25.1) | 12.5 (8.7 to 17.7) |
| PR (95% CI) | 1.00* | 0.91 (0.69 to 1.19) | 0.88 (0.62 to 1.25) | 0.81 (0.56 to 1.19) |
*Denotes the reference group for the PR.
Prevalence and age-adjusted prevalence ratios (PRs) of diabetes, hypertension and associated risk factors by occupational grade in the adult Barbadian population
| Routine/manual | Intermediate | Professional | |
|---|---|---|---|
| Women | |||
| Prevalence (%) (95% CI) | 4.8 (1.4 to 15.5) | 2.0 (0.9 to 4.4) | 7.4 (2.8 to 18.1) |
| PR (95% CI) | 1.00* | 0.37 (0.08 to 1.64) | 1.46 (0.32 to 6.71) |
| Men | |||
| Prevalence (%) (95% CI) | 18.1 (12.4 to 25.7) | 24.4 (13.5 to 40) | 1.1 (0.1 to 8.4) |
| PR (95% CI) | 1.00* | 1.28 (0.67 to 2.45) | 0.06 (0.01 to 0.52) |
| Total | |||
| Prevalence (%) (95% CI) | 14.0 (9.8 to 19.6) | 9.1 (5.2 to 15.4) | 4.5 (1.9 to 10.6) |
| PR (95% CI) | 1.00* | 0.98 (0.49 to 1.96) | 0.39 (0.16 to 0.96) |
| Women | |||
| Prevalence (%) (95% CI) | 5.0 (1.9 to 12.7) | 4.4 (1.7 to 10.6) | 9.3 (4.9 to 16.9) |
| PR (95% CI) | 1.00* | 0.60 (0.15 to 2.41) | 1.38 (0.41 to 4.64) |
| Men | |||
| Prevalence (%) (95% CI) | 24.1 (17.0 to 33.0) | 30.2 (18.5 to 45.1) | 23.2 (14.4 to 35.2) |
| PR (95% CI) | 1.00* | 1.21 (0.65 to 2.27) | 0.98 (0.56 to 1.72) |
| Total | |||
| Prevalence (%) (95% CI) | 18.2 (13.1 to 24.7) | 12.5 (8.1 to 18.9) | 15.6 (10.2 to 23.2) |
| PR (95% CI) | 1.00* | 1.08 (0.61 to 1.92) | 1.09 (0.67 to 1.77) |
| Women | |||
| Prevalence (%) (95% CI) | 89.1 (78.7 to 94.7) | 86.5 (79.6 to 91.3) | 81.7 (73.7 to 87.7) |
| PR (95% CI) | 1.00* | 0.70 (0.32 to 1.53) | 0.52 (0.25 to 1.12) |
| Men | |||
| Prevalence (%) (95% CI) | 89.4 (81.1 to 94.3) | 91.3 (81.2 to 96.3) | 96.2 (89 to 98.8) |
| PR (95% CI) | 1.00* | 1.23 (0.57 to 2.67) | 2.82 (0.81 to 9.90) |
| Total | |||
| Prevalence (%) (95% CI) | 89.3 (83.7 to 93.1) | 88.0 (81.9 to 92.3) | 88.4 (83 to 92.3) |
| PR (95% CI) | 1.00* | 1.02 (0.65 to 1.61) | 0.97 (0.58 to 1.63) |
| Women | |||
| Prevalence (%) (95% CI) | 67.7 (57.4 to 76.5) | 65.0 (57.4 to 71.9) | 62.5 (52.2 to 71.8) |
| PR (95% CI) | 1.00* | 0.97 (0.83 to 1.14) | 0.97 (0.82 to 1.15) |
| Men | |||
| Prevalence (%) (95% CI) | 27.8 (21.2 to 35.5) | 33.6 (24.8 to 43.7) | 34.1 (24.3 to 45.3) |
| PR (95% CI) | 1.00* | 1.19 (0.92 to 1.54) | 1.23 (0.87 to 1.75) |
| Total | |||
| Prevalence (%) (95% CI) | 40.0 (33.9 to 46.5) | 55.0 (48.6 to 61.3) | 49.3 (41.8 to 56.7) |
| PR (95% CI) | 1.00* | 1.02 (0.88 to 1.18) | 1.04 (0.9 to 1.2) |
| Women | |||
| Prevalence (%) (95% CI) | 48.0 (38.8 to 57.4) | 44.8 (38 to 51.9) | 40.7 (31.6 to 50.5) |
| PR (95% CI) | 1.00* | 0.85 (0.64 to 1.15) | 0.78 (0.55 to 1.11) |
| Men | |||
| Prevalence (%) (95% CI) | 21.4 (15.8 to 28.4) | 33.2 (22.6 to 45.9) | 28.1 (15.7 to 45) |
| PR (95% CI) | 1.00* | 1.51 (0.94 to 2.42) | 1.28 (0.69 to 2.36) |
| Total | |||
| Prevalence (%) (95% CI) | 29.4 (24.3 to 35.1) | 41.0 (34.7 to 47.6) | 34.6 (26.1 to 44.3) |
| PR (95% CI) | 1.00* | 1.07 (0.79 to 1.45) | 0.99 (0.69 to 1.41) |
| Women | |||
| Prevalence (%) (95% CI) | 28.7 (19.7 to 39.9) | 23.8 (17 to 32.2) | 13.8 (8.9 to 20.8) |
| PR (95% CI) | 1.00* | 0.99 (0.63 to 1.56) | 0.58 (0.36 to 0.94) |
| Men | |||
| Prevalence (%) (95% CI) | 22.0 (15.4 to 30.5) | 14.2 (7.3 to 25.8) | 15.3 (7.1 to 29.7) |
| PR (95% CI) | 1.00* | 0.66 (0.29 to 1.51) | 0.69 (0.32 to 1.46) |
| Total | |||
| Prevalence (%) (95% CI) | 23.9 (18.5 to 30.4) | 20.8 (15.2 to 27.7) | 14.5 (9.5 to 21.4) |
| PR (95% CI) | 1.00* | 0.86 (0.57 to 1.29) | 0.60 (0.38 to 0.94) |
| Women | |||
| Prevalence (%) (95% CI) | 56.5 (45.3 to 67.1) | 38.0 (31.2 to 45.2) | 33.0 (23.5 to 44) |
| PR (95% CI) | 1.00* | 1.08 (0.91 to 1.28) | 0.90 (0.67 to 1.2) |
| Men | |||
| Prevalence (%) (95% CI) | 35.1 (26.3 to 45.1) | 35.8 (25.9 to 47.1) | 38.6 (27.9 to 50.4) |
| PR (95% CI) | 1.00* | 1.08 (0.81 to 1.45) | 1.06 (0.77 to 1.44) |
| Total | |||
| Prevalence (%) (95% CI) | 41.7 (34.3 to 49.4) | 37.3 (31.7 to 43.2) | 35.6 (28.4 to 43.4) |
| PR (95% CI) | 1.00* | 1.09 (0.93 to 1.27) | 0.97 (0.80 to 1.17) |
| Women | |||
| Prevalence (%) (95% CI) | 32.7 (21.6 to 46.2) | 15.7 (11.1 to 21.6) | 17.4 (10.7 to 27.1) |
| PR (95% CI) | 1.00* | 0.72 (0.48 to 1.07) | 0.73 (0.42 to 1.29) |
| Men | |||
| Prevalence (%) (95% CI) | 14.1 (9.0 to 21.5) | 14.5 (7.6 to 26.1) | 17.3 (9.7 to 29.0) |
| PR (95% CI) | 1.00* | 1.26 (0.65 to 2.45) | 1.39 (0.76 to 2.56) |
| Total | |||
| Prevalence (%) (95% CI) | 19.6 (15.1 to 25.1) | 15.3 (10.6 to 21.5) | 17.4 (11.5 to 25.2) |
| PR (95% CI) | 1.00* | 0.90 (0.58 to 1.39) | 0.98 (0.62 to 1.54) |
*Denotes the reference group for the PR.